Health for all Children

Chapter 9 References

Where possible we have provided additional details of websites referenced, see the Support Directory.

page
197 National newborn screening programme
197 Neonatal screening
201 Down’s Syndrome Medical Interest Group
204 Screening for neuroblastoma

Page 197: National newborn screening programme
Streetly A,.Corbett V. The national newborn screening programme : an audit of phenylketonuria and congenital hypothyroidism screening in England and Wales. London: Department of Public Health Medicine, UMDS Guy’s and St Thomas’s Medical Schools. 1998.

Page 197: Neonatal screening
Neonatal screening for inborn errors of metabolism: a systematic review. Seymour C A, Thomason M J, R A Chalmers, Addison G M, Bain M D, Cockburn F, Littlejohns P, Lord J, Wilcox A H. Health Technology Assessment 1997; Vol. 1: No. 11.
Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Pollitt R J, Leonard J V, Green A, Nicholl J, McCabe C J, Nicholson P, Booth A, Tunaley J R, Cooper N J, Virdi N K. Health Technology Assessment 1997; Vol. 1: No. 7.
Both can be ordered at www.hta.nhsweb.nhs.uk

Page 201: Down’s Syndrome Medical Interest Group
Down’s Syndrome Medical Interest Group website www.dsmig.org.uk

Page 204: Screening for neuroblastoma
Woods W G, Tuchman M, Robison L L, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996;348:1682-87.Bessho F. Where should neuroblastoma mass screening go? Lancet 1996;348:1672
Powell J E, Estève J, Mann J R, et al. Neuroblastoma in Europe: difference in the pattern of disease in the UK. Lancet 1998;352:682-87.
Woods W G. Unravelling mysteries of neuroblastoma. Lancet 1998;352:667-68.
Suita S. Mass screening for neuroblastoma in Japan: Lessons learned and future directions. Journal of Pediatric Surgery 2002;37:949-954.